Categories AlphaGraphs, Cannabis, Earnings

ACB Earnings Infographic: Aurora Cannabis Q2 2023 revenue rises

Aurora Cannabis, Inc. (NASDAQ: ACB) on Friday reported a narrower net loss for the second quarter of 2023. The company’s revenues moved up 2% year-over-year during the quarter.

The Canada-based medical marijuana company reported a net loss from continuing operations of C$67.2 million for the second quarter, compared to a loss of C$75.1 million in the year-ago period. Adjusted EBITDA was C$1.4 million during the three-month period, compared to a loss of C$7.1 million in the prior-year quarter. Total revenues increased 2% annually to C$61.7 million.

Read management/analysts’ comments on quarterly reports

“We have right-sized our business while remaining the #1 Canadian LP in global medical cannabis revenues, and having demonstrated organic quarter-over-quarter revenue growth across all of our cannabis segments during Q2 2023,” said Miguel Martin, chief executive officer of Aurora Cannabis.

Prior Performance

  • Aurora Cannabis Q4 2022 earnings infographic
  • Aurora Cannabis Q3 2022 earnings infographic
  • Aurora Cannabis Q2 2022 earnings infographic
  • Aurora Cannabis Q1 2022 earnings infographic

Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!

Most Popular

Key takeaways from Cintas’ (CTAS) third-quarter 2023 report

Cintas Corporation (NASDAQ: CTAS) has been growing its market share by diversifying into new areas and through acquisitions. The prudent business model, with a focus on recurring revenues, has helped

Here are a few points to keep in mind if you are considering Starbucks Corporation (SBUX)

Shares of Starbucks Corporation (NASDAQ: SBUX) stayed in green on Thursday. The stock has gained 10% over the past 12 months. The company delivered healthy results for its most recent

ANGO Earnings: AngioDynamics reports loss for Q3; revenue up 9%

AngioDynamics Inc. (NASDAQ: ANGO) on Thursday reported a wider loss for the third quarter when the medical device maker's revenues increased by 9%. The company also provided guidance for fiscal

Add Comment
Viewing Highlight